

Acinetobacter baumannii, Strain MRSN 489678

Catalog No. NR-52247

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (*A. baumannii*), strain MRSN 489678 was isolated in 2014 from a human wound sample in Europe as part of a global surveillance program. *A. baumannii*, strain MRSN 489678 was deposited as multi-locus sequence type (MLST) ST 19, sensitive to amikacin, colistin, cefepime, imipenem, meropenem, ampicillin/sulbactam and tetracycline, intermediately resistant to tobramycin and resistant to ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, levofloxacin and trimethoprim/sulfamethoxazole. NR-52247 was produced by inoculation of BEI Resources lot 70041188 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70060476

Manufacturing Date: 03MAY2023

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology Growth at 44°C ± 2°C ¹ 1 day in an aerobic atmosphere on Tryptic Soy agar Motility Hardy Diagnostics™ Motility Test Medium with TTC Indicator for 1 day at 37°C in an aerobic atmosphere VITEK® MS (MALDI-TOF)	Gram-negative rods Report results Growth Non-motile <i>A. baumannii</i>	Gram-negative rods Circular, convex, entire, smooth and cream Growth ² Non-motile <i>A. baumannii</i> (99.9%)
Antibiotic Susceptibility Profile^{3,4} Amikacin Ampicillin/sulbactam Cefepime Ceftazidime Ceftriaxone Ciprofloxacin Gentamicin Imipenem Levofloxacin Meropenem Tetracycline Tobramycin Trimethoprim/sulfamethoxazole	Sensitive Sensitive Sensitive Resistant Resistant Resistant Resistant Sensitive Resistant Sensitive Resistant Intermediate Resistant	Sensitive (0.38 µg/mL) Sensitive (1.5 µg/mL) Sensitive (4 µg/mL) Resistant (48 to 64 µg/mL) Resistant (≥ 64 µg/mL) Resistant (≥ 4 µg/mL) Intermediate (6 µg/mL) ⁵ Sensitive (0.125 µg/mL) Resistant (≥ 8 µg/mL) Sensitive (≤ 0.25 µg/mL) Resistant (16 µg/mL) Sensitive (4 µg/mL) ⁶ Resistant (160 µg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1460 base pairs)	≥ 99% sequence identity to <i>A. baumannii</i> , strain MRSN 489678 (GenBank: VHEN01000084.1)	99.9% sequence identity to <i>A. baumannii</i> , strain MRSN 489678 (GenBank: VHEN01000084.1)

Certificate of Analysis for NR-52247

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere on Tryptic Soy agar 7 days at 37°C in an aerobic atmosphere with 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology Growth consistent with expected colony morphology	Growth consistent with expected colony morphology Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus* and *A. pittii*, which do not grow at 44°C.

²Two colony types were observed. The 16S ribosomal RNA gene of each colony type was sequenced and found to be consistent with the other colony type and *A. baumannii*, strain MRSN 489678.

³Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

⁴Antibiotic susceptibility was tested using a combination of bioMérieux VITEK®2 GN81 and ETEST®.

⁵*K. pneumoniae*, strain MRSN 489678 was deposited as resistant to gentamycin, but showed a MIC of 6 µg per mL (interpreted as intermediate) for this antibiotic during QC testing. Testing was performed in duplicate.

⁶The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

/Sonia Bjorum Brower/

Sonia Bjorum Brower

05 JUL 2023

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

